Charles River Laboratories International, Inc. (CRL)

Market Cap	8.25B
Revenue (ttm)	4.02B
Net Income (ttm)	-83.48M
Shares Out	49.22M
EPS (ttm)	-1.67
PE Ratio	n/a
Forward PE	15.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,342,710
Open	163.59
Previous Close	162.08
Day's Range	157.49 - 172.39
52-Week Range	91.86 - 203.01
Beta	1.64
Analysts	Buy
Price Target	190.15 (+13.43%)
Earnings Date	Nov 5, 2025

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 20,100
• Stock Exchange: NYSE
• Ticker Symbol: CRL
• Website: https://www.criver.com

Financial Performance

In 2024, CRL's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.

Analyst Summary

According to 15 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $190.15, which is an increase of 13.43% from the latest price.

Price Target

$190.15

(13.43% upside)

Analyst Consensus: Buy